{
  "docId": "019de071-a0aa-74fc-b780-f72cc7f02158",
  "docSlug": "6af314fff9e6eaaf966098f4c73a6229",
  "documentTitle": "Mink Therapeutics | IPO Presentation Deck | 36 slides",
  "authorId": "mink-therapeutics",
  "authorName": "MiNK Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7860465,
  "pageNumber": 35,
  "pageCount": 36,
  "prevPage": 34,
  "nextPage": 36,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide justifies the clinical trial strategy by citing small sample sizes and surrogate endpoints.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-a0aa-74fc-b780-f72cc7f02158/35",
  "deckHref": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158",
  "deckJsonHref": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158.json",
  "deckAnchorHref": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158#slide-35",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.84,
        "x": 0.08,
        "y": 0.275
      },
      "kind": "paragraph",
      "text": "Acute GVHD is eligible for accelerated development based on efficient clinical trials (ie small sample sizes) and surrogate endpoints (ie response rates)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cab8a3c0-411b-4e0c-8bf5-b4e288f8df21",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.28,
        "x": 0.06,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "1. Currently in the process of preparing IND application\n2. Including but not limited to the indications listed",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7c201e43-aa56-4fbe-b81a-ab8a08be264d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.84,
        "x": 0.08,
        "y": 0.375
      },
      "kind": "table",
      "text": "Indication | AGENT-797 (iNKT cells) | Endpoints\nPhase 1/2 | Acute GVHD | Expected to be 3+3 up to 1x10^9 iNKT cells (AGENT-797) patients undergoing HSCT to evaluate engraftment success and GVHD mitigation | Safety, Persistence, Engraftment success, Response rates",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b2a110b-c9f6-4330-8922-99346ddf514b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.76,
        "x": 0.12,
        "y": 0.04
      },
      "kind": "title",
      "text": "Phase 1/2 Clinical Trial Focused in Acute GVHD",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca2cc984-e666-435c-86f7-791db05de369",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "e6068569-f76a-4756-bcb9-1983405a6ec6",
      "evidence": "The slide features a table with data on 'Indication', 'AGENT-797 (iNKT cells)', and 'Endpoints' for the Phase 1/2 clinical trial in Acute GVHD.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 36,
      "from": 35,
      "beatId": "df9de426-4cf6-4a90-b675-ffce826d458b",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Financials",
      "beatSlug": "sequoia-pitch-financials",
      "evidence": "The document includes data on clinical trials and potential financial opportunities.",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 36,
      "from": 5,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "ff1f25c5-6e00-4a50-9457-841955937c0b",
      "evidence": "The document presents the why, what, and how of MiNK's iNKT cell therapies throughout the deck.",
      "position": 0,
      "objective": "Why MiNK Therapeutics' iNKT cell therapies are needed and how they work",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}